SHP611
SHP611-201
Phase 2 small_molecule active
Quick answer
SHP611 for Metachromatic Leukodystrophy (MLD) is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Metachromatic Leukodystrophy (MLD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active